Claude Bernard Prize
The Claude Bernard Prize recognises an individual's innovative leadership and lifetime achievements in diabetes research.
To be eligible for nomination
- Candidates must be an EASD member
- Candidates can be from any country
- There are no age restrictions
The awardee will receive a monetary prize generously sponsored by Sanofi and will deliver a Lecture during the EASD Annual Meeting in the year of the award describing the awardee’s most important scientific achievements.
Learn more about the 2024 Claude Bernard Prize awardee
Roy Taylor, United Kingdom
Lecture: The aetiology of type 2 diabetes: an experimental medicine odyssey
Awardee Portrait
Awardee Interview
Claude Bernard Awardees:
2024 Madrid
R. Taylor (UK): The aetiology of type 2 diabetes: an experimental medicine odyssey
2023 Hamburg
Å. Lernmark (SE): Dissecting etiologies of autoimmune type 1 diabetes
2022 Stockholm
M.A. Nauck (DE): An updated incretin concept for tomorrow
2021 Virtual Meeting
J.R. Zierath (SE): Sending the right signals: How exercise keeps the rhythm in metabolism
2020 Virtual Meeting
T. Kadowaki (JP): What is type 2 diabetes? A long journey to seek the truth
2019 Barcelona
S.E. Kahn (US): Unravelling beta cell dysfunction in type 2 diabetes: from the unpredicted to the unknown
2018 Berlin
J. Tuomilehto (KW): Prevention of type 2 diabetes: a dream that came true
2017 Lisbon
B. Thorens (CH): A glucose-centric view on diabetes pathogenesis: from islet biology to integrated physiology and precision medicine
2016 Munich
M.E. Cooper (AU): Uncomplicating diabetes: interactions between metabolic and haemodynamic signalling pathways in the pathogenesis of diabetic complications
2015 Stockholm
H.-U. Häring (DE): Understanding phenotypes of prediabetes: essential to influencing progression to type 2 diabetes
2014 Vienna
D. Accili (US): The new biology of diabetes
2013 Barcelona
M. Laakso (FI): From one family to 10,000 men: genes meet phenotypes in diabetes
2012 Berlin
D. Drucker (CA): Understanding incretin hormone action and the treatment of diabetes
2011 Lisbon
E. Ferrannini (IT): Diabetes: brief history of a conspiracy
2010 Stockholm
M. Kasuga (JP): Unravelling the insulin signalling network to understand and treat diabetes
2009 Vienna
O. Pedersen (DK): From cost-effective whole-patient diabetes care to diminish vascular morbidity and mortality - towards the potentials of biomarker-promoted metabolic health
2008 Rome
R.A. deFronzo (US): Insulin resistance, lipotoxicity, and ASCVD: the missing link
2007 Amsterdam
E. Van Obberghen (FR): Diabetes and its complications: insulin action in trouble
2006 Copenhagen
L. Groop (SE): The genetic complexity of type 2 diabetes - from nightmare to sunrise
2005 Athens
J.J. Holst (DK): Treatment of type 2 diabetes mellitus based on incretin action: status and perspectives
2004 Munich
C.R. Kahn (US): The brain and tissue communication in the pathogenesis of diabetes: Claude Bernard revisited
2003 Paris
M. Brownlee (US): Biochemistry and molecular cell biology of diabetic complications
2002 Budapest
M.-R. Taskinen (FI): Diabetic dyslipidaemia: From research to practice
2001 Glasgow
P.E. Cryer (US): Hypoglycaemia: The limiting factor in the management of type 1 and type 2 diabetes
2000 Jerusalem
W. Malaisse (BE): On the track to the beta cell
1999 Brussels
J.-P. Assal (CH): From bio-medicine to patient needs: Which cybernetic challenges in diabetes therapy? Some unanswered questions
1998 Barcelona
C. Wollheim (CH): Mitochondria and and beta-cell function: A new culprit in type 2 diabetes
1997 Helsinki
C.E. Morgensen (DK): Microalbuminuria and diabetic renal disease. Origin and development of ideas
1996 Vienna
J.D. Ward (UK): The tragedy and challenge of diabetic neuropathy
1995 Stockholm
M. Berger (DE): To bridge science and patient care in diabetes
1994 Düsseldorf
G. Reaven (US): The fourth Musketeer - from Alexandre Dumas to Claude Bernard
1993 Istanbul
D. Andreani (IT): The labyrinth of diabetic vascular disease: Crossroads and ways out
1992 Prague
P.H. Bennett(US): Epidemiology, pathogenesis and genetics of NIDDM: From Claude Bernard to the Pima Indians
1991 Dublin
E. Shafrir (IL): Understanding of diabetes through studies of its aetiopathology in animals
1990 Copenhagen
K.G. Alberti (UK): Insulin resistance: mechanisms, measurement and meaning
1989 Lisbon
G. Tchobroutsky (FR): Blood sugar levels in diabetics and non-diabetics
1988 Paris
T. Deckert (DK): Albuminuria reflects widespread vascular damage
1987 Leipzig
H. Keen (UK): The bad companions
1986 Rome
W.K. Waldhäusl (AT): The physiological basis of insulin treatment: Clinical aspects
1985 Madrid
E.F. Pfeiffer (DE): On the way to automated control of blood sugar in diabetes: The dark past, the grey present and the rosy future
1984 London
P.J. Lefébvre (BE): From plant physiology to human metabolic investigations
1983 Oslo
C. Hellerström (SE): The life story of a beta cell
1982 Budapest
J. Mirouze (FR): Insulin treatment: A non-stop revolution
1981 Amsterdam
G.R. Meyer-Schwickerath (DE): Doseology of photocoagulation in diabetic retinopathy
1980 Athens
R.H. Unger (US): The milieu interieur and the islets of Langerhans
1979 Vienna
D.A. Pyke (UK): Diabetes: The genetic connections
1978 Zagreb
W. Creutzfeldt (DE): The incretin concept today (with special reference to GIP)
1977 Geneva
D.L. Coleman (US): Diabetes syndromes in mice
1976 Helsinki
H.G. Hers (BE): The homeostatic and hormonal control of the level of glycaemia by the liver
1975 Munich
R.G. Spiro (US): Search for a biochemical basis of diabetic microangiopathy
1974 Jerusalem
T.R. Fraser (UK): Insulin's calcium releasing action
1973 Brussels
A.E. Renold (CH): Experimental and spontaneous diabetic syndromes in animals (a re-evaluation of their usefulness for approaching the physio-pathology of diabetes in man)
1972 Madrid
K. Lundbaek (DK): Diabetic angiopathy
1971 Southampton
M. Dérot (FR): Progrès dans l'investigation et le traitement des acidocétoses diabétiques sévères
1970 Warsaw
E.W. Sutherland (US): The regulatory role of cyclic AMP
1969 Montpellier
C. de Duve (BE): Lysosomes, cellular pathology and diabetes